Lecciones y propuestas tras una estrategia exitosa frente al VRS: experiencia chilena con Nirsevimab en la temporada 2024 y desafíos para el periodo 2025-2027.

Saved in:

Bibliographic Details
Title:	Lecciones y propuestas tras una estrategia exitosa frente al VRS: experiencia chilena con Nirsevimab en la temporada 2024 y desafíos para el periodo 2025-2027.
Alternate Title:	Lessons and proposals after a successful strategy against RSV: the Chilean experience with nirsevimab during the 2024 season and challenges for the 2025-2027 period.
Authors:	Paris, Enrique¹ enriqueparism@gmail.com, Pablo Diaz, Juan^1,2, Castillo, Andrés^1,3, Tapia, Lorena^1,4, González, Cecilia^1,5, Zamorano, Alejandra^1,6, Luz Endeiza, María^1,7, Zamorano, Juana^1,8, González, Jaime^1,9, J. Basso, Leonardo^1,10, Sauré, Denis^1,10, Cisternas, Paula^1,11,12, Escárate, Raúl^1,13, Pablo Moreno, Juan^1,14
Source:	Andes Pediatrica. Jan/Feb2026, Vol. 97 Issue 1, p14-22. 9p.
Subjects:	RESPIRATORY syncytial virus infection vaccines, IMMUNIZATION of children, RESPIRATORY infections in children, INFANT mortality, MONOCLONAL antibodies, RESPIRATORY syncytial virus, HEALTH policy
Geographic Terms:	SOUTHERN Hemisphere, CHILE
Abstract (English):	For decades, Respiratory Syncytial Virus (RSV) has been one of the leading causes of morbidity and mortality in infants in Chile and worldwide. The 2023 season, marked by an early and severe outbreak, highlighted the limitations of the health system in dealing with this virus, generating broad consensus on the need for a more robust, preventive, and intersectoral strategy. In this context, the creation of the RSV Coalition -an articulated effort between former health authorities, scientific societies, universities, and clinical and technical experts-made it possible to design and promote a series of recommendations that played a significant role in the decision-making process by the health authorities at the time. These efforts materialized in 2024 with the pioneering incorporation of the monoclonal antibody Nirsevimab into the National Immunization Program. Chile thus became the first country in the Southern Hemisphere to implement a national and universal RSV immunization strategy, achieving high coverage rates and substantial reductions in hospitalizations. This article aims to document the positive outcomes of this implementation, as well as to critically reflect on the factors that made it possible, to identify remaining gaps, and -above all- to project the decisions required to prevent setbacks and move toward a sustainable, equitable, evidence-based prevention policy against RSV and other childhood respiratory infections. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Durante décadas, el Virus Respiratorio Sincicial (VRS) ha representado una de las principales causas de morbilidad y mortalidad en lactantes en Chile y el mundo. La experiencia del año 2023, marcada por un brote anticipado y severo, visibilizó las limitaciones del sistema sanitario frente a este virus, generando un consenso transversal respecto a la necesidad de una estrategia más robusta, preventiva e intersectorial. En este contexto, la conformación de la Coalición VRS -un esfuerzo articulado entre ex autoridades sanitarias, sociedades científicas, universidades, expertos clínicos y técnicos-permitió diseñar e impulsar una serie de recomendaciones que fueron importantes en la toma de decisiones de las autoridades sanitarias de la época, materializándose el 2024, con la incorporación pionera del anticuerpo monoclonal Nirsevimab al Programa Nacional de Inmunizaciones. Chile se convirtió así en el primer país del hemisferio sur en ejecutar una estrategia nacional y universal de inmunización contra el VRS, alcanzando altas coberturas y reducciones sustantivas en hospitalizaciones. Este artículo busca documentar los resultados positivos de esa implementación, como también reflexionar críticamente sobre los factores que la hicieron posible, identificar brechas aún pendientes y en especial proyectar las decisiones necesarias para evitar retrocesos y avanzar hacia una política de prevención sostenible, equitativa y basada en evidencia frente al VRS y otras infecciones respiratorias infantiles. [ABSTRACT FROM AUTHOR]
	Copyright of Andes Pediatrica is the property of Revista Chilena de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	For decades, Respiratory Syncytial Virus (RSV) has been one of the leading causes of morbidity and mortality in infants in Chile and worldwide. The 2023 season, marked by an early and severe outbreak, highlighted the limitations of the health system in dealing with this virus, generating broad consensus on the need for a more robust, preventive, and intersectoral strategy. In this context, the creation of the RSV Coalition -an articulated effort between former health authorities, scientific societies, universities, and clinical and technical experts-made it possible to design and promote a series of recommendations that played a significant role in the decision-making process by the health authorities at the time. These efforts materialized in 2024 with the pioneering incorporation of the monoclonal antibody Nirsevimab into the National Immunization Program. Chile thus became the first country in the Southern Hemisphere to implement a national and universal RSV immunization strategy, achieving high coverage rates and substantial reductions in hospitalizations. This article aims to document the positive outcomes of this implementation, as well as to critically reflect on the factors that made it possible, to identify remaining gaps, and -above all- to project the decisions required to prevent setbacks and move toward a sustainable, equitable, evidence-based prevention policy against RSV and other childhood respiratory infections. [ABSTRACT FROM AUTHOR]
ISSN:	24526045
DOI:	10.32641/andespediatr.v97i1.5945